Unveiling the pulmonary burden of idiopathic inflammatory myopathies in South Africa

Main Article Content

G L Calligaro

Abstract

-

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Calligaro GL. Unveiling the pulmonary burden of idiopathic inflammatory myopathies in South Africa. Afr J Thoracic Crit Care Med [Internet]. 2024 Oct. 14 [cited 2025 Apr. 26];30(3):e2682. Available from: https://samajournals.co.za/index.php/ajtccm/article/view/2682
Section
Editorials

How to Cite

1.
Calligaro GL. Unveiling the pulmonary burden of idiopathic inflammatory myopathies in South Africa. Afr J Thoracic Crit Care Med [Internet]. 2024 Oct. 14 [cited 2025 Apr. 26];30(3):e2682. Available from: https://samajournals.co.za/index.php/ajtccm/article/view/2682

References

1. Milone M. Diagnosis and management of immune-mediated myopathies. Mayo Clin Proc 2017;92(5):826-837. https://doi.org/10.1016/j.mayocp.2016.12.025

2. Hes T, Wong M, Tikly M, Govind N. Pulmonary manifestations of the idiopathic inflammatory myopathies in a South African population. Afr J Thoracic Crit Care Med 2024;30(3):e1663. https://doi.org/10.7196/AJTCCM.2024.v30i3.1663

3. LongK,DanoffSK.Interstitiallungdiseaseinpolymyositisanddermatomyositis.Clin Chest Med 2019;40(3):561-572. https://doi.org/10.1016/j.ccm.2019.05.004

4. Kiely PD, Chua F. Interstitial lung disease in inflammatory myopathies: Clinical phenotypes and prognosis. Curr Rheumatol Rep 2013;15(9):359. https://doi. org/10.1007/s11926-013-0359-6

5. Cobo-Ibáñez T, López-Longo F-J, Joven B, et al. Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease. Clin Rheumatol 2019;38(3):803-815. https://doi.org/10.1007/s10067- 018-4353-2

6. Vu TTT, Brown KK, Solomon JJ. Myositis-associated interstitial lung disease. Curr Opin Pulm Med 2023;29(5):427-435. https://doi.org/10.1097/MCP.0000000000001000 7. Chang S, Shin MH, Shin JH, Park MS. Clinical characteristics of anti-Jo-1-positive interstitial lung disease. Eur Respir J 2019;54(Suppl 63):PA5183. https://doi.

org/10.1183/13993003.congress-2019.PA5183

8. Ndamase S, Okpechi I, Carrara H, Black J, Calligaro G, Freercks R. Tuberculosis burden in stage 5 chronic kidney disease patients undergoing dialysis therapy at Livingstone Hospital, Port Elizabeth, South Africa. S Afr Med J 2020;110(5):422-426. https://doi.org/10.7196/SAMJ.2020.v110i5.14035

9. Torre-CisnerosJ,DoblasA,AguadoJM,etal.Tuberculosisaftersolid-organtransplant: Incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009;48(12):1657-1665. https://doi.org/10.1086/599035

10. Yuan Z, Chao S, Xu Y, Niu Y. Chemoprophylaxis for the prevention of tuberculosis in kidney transplant recipients: A systematic review and meta-analysis. Front Pharmacol 2023;14:1022579. https://doi.org/10.3389/fphar.2023.1022579